Global Low Molecular Weight Heparin Market: Key Developments
In March 2022, Valeo Pharma Inc., pharmaceutical company based in Canada announced that it has successfully entered into a Product Listing Agreement (PLA) with the British Columbia Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP(are the first LMWH biosimilars to be approved by Health Canada), its low molecular weight heparin ("LMWH") biosimilar for the prevention and treatment of thromboembolic disorders, on the British Columbia PharmaCare list of medications, effective on March 22, 2022.
Low Molecular Weight Heparin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients